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Proteolytical processing of membrane boundmolecules is a fundamental mechanism for
the degradation of these proteins as well as for controlling cell-to-cell communication,
which is at the basis of tissue development and homeostasis. Members of families of
metalloproteinases and intra-membrane proteases are major effectors of these events.
A recent workshop in Baeza, Spain, was devoted to discuss how this mechanism
coordinates brain development and how its dysfunction leads to brain pathologies.
Herein we summarize the findings presented during this workshop, which illuminate
the role of metalloproteinases, including matrix metalloproteinase, A Disintegrin and
Metalloproteinase-proteases and intra-membrane proteases, in the regulation of
neurogenesis, axon guidance, and synaptogenesis as well as in neurodegeneration.
Indeed, there is increasing evidence that proteolysis at the membrane is directly
linked to neuropathologies such as Alzheimer Disease and autism spectrum or prion
disorders. These proteolytic events are tightly regulated and we are just at the beginning
of understanding how these processes could be exploited to design therapeutic
treatments aimed at alleviating psychiatric and neurodegenerative pathologies.
Keywords: neurogenesis, axon guidance, synapse formation, stem cells, ADAM, presenilin, neurodegeneration,
prion
Introduction
The highest functions of the nervous system, including the cognitive capabilities of the human
brain, are rooted on stereotyped and yet plastic interactions among a huge variety of neurons
and glial cells, which compose the vertebrate brain. The speciﬁcation of neural cells occurs with
an apparently invariable precision during a protracted period of the embryonic and early post-
natal life (Albright et al., 2000). In turn, the molecular information acquired by the diﬀerent
neuronal types is fundamental to select and restrict the establishment of brain circuit and to
modify the way in which information is processed (Zipursky and Sanes, 2010). All these events
need to be highly coordinated in time and space with mechanisms that control how the ﬂow
of information among cells is switched oﬀ or prolonged. Therefore, understanding how the
human brain is built requires the full comprehension of this diversity and of the mechanisms
that ﬁnely control the formation and the posterior plasticity of neuronal circuits (Emes and
Grant, 2012). This, in turn, is a prerequisite to identify the molecular basis of the abnormali-
ties associates with the many disorders that aﬀects the diﬀerent structures of the brain and their
function.
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Proteolytical processing of membrane bound molecules
acquires particular importance in the context of the brain since
its function strongly depends on well-orchestrated interactions
among many diﬀerent cell types, including neurons and glial
cells. Members of families of metalloproteinases are major eﬀec-
tors of these events. The meeting “Proteases at work: cues for
understanding neural development and degeneration” which
took place in Baeza, Spain from October 20th until October
23rd, 2014 brought together internationally recognized leaders
in the ﬁeld to summarize the most recent evidence demon-
strating that proteases are essential for the development of the
CNS, underscoring their relevance in neurodegeneration and dis-
cussing whether endogenous or pharmacological modulation of
their activity represents a therapeutic tool.
Carl Blobel (Hospital for Special Surgery, NewYork, NY, USA)
initiated the conference by providing an overview about pro-
teinases belonging to the A Disintegrin and Metalloproteinase
Family (ADAMs). ADAMs regulate the fate of cell surface
expressed membrane proteins (Blobel, 2005; Weber and Saftig,
2012; Figure 1). He focused on a speciﬁc member of this family,
ADAM17, and its well-established role in liberating Epidermal
Growth Factor Receptor ligands from their membrane-anchor.
As for the other proteolytically active members of the ADAM
family, their regulation still remains a ﬁeld with many open ques-
tions. In this regard, the inactive Rhomboid1 and 2 (iRhom)
proteins turned out to be instrumental upstream regulators for
ADAM17/EGFR signaling. iRhom2 controls the substrate selec-
tivity of stimulated ADAM17-dependent ectodomain shedding
(Maretzky et al., 2013). Its interaction with ADAM17 controls the
cellular traﬃcking of the protease and its maturation in myeloid
cells (Figure 1A). Disruption of both iRhoms genes in mice led
to a phenotype comparable to the ADAM17 and EGFR-knockout
mice providing clear evidence that ADAM17 is tightly controlled
by both iRhoms.
Metalloproteinases in Brain
Closely related to ADAM17, ADAM10 exerts a number of essen-
tial functions related to the development and function of the
brain. ADAM10 sheds the amyloid precursor protein (APP), the
Notch receptor, and the prion protein (Weber and Saftig, 2012).
Paul Saftig (University Kiel, Germany) reported about a num-
ber of additional neuronal substrates of ADAM10. Conditional
knockout mice with disruption of ADAM10 in the developing
or adult brain revealed diﬀerent and stage-dependent functions
of this protease. ADAM10 controls cell fate decision events with
a process that depends on the cleavage of the Notch recep-
tor and that discriminates between neurogenesis and gliogenesis
(Jorissen et al., 2010). In adult neurons, ADAM10 contributes
to synaptogenesis mediating cleavage of adhesion proteins at
the synapse (Figure 1B). Spine development, synapse plastic-
ity, synaptic network function, memory, and learning all rely
on proper cell-autonomous activity of ADAM10 (Prox et al.,
2013). ADAM10 itself can be shedded by ADAM9 or ADAM15.
It is thus conceivable that the glia-derived ADAM10-ectodomain
could also contribute to synapse shaping in trans. Interestingly,
FIGURE 1 | (A) Illustration of an A Disintegrin and Metalloproteinase (ADAM)
protease, which is regulated by tetraspanin proteins (e.g., shown for ADAM10)
and inactive rhomboids (shown for ADAM17). The cleavage of a membrane
bound substrate protein is a hallmark of the process termed “ectodomain
shedding.” It regulates the function of this cell surface protein and its half-life.
(B) Proteases play a central role in both excitatory and inhibitory synapse
biology and function. ADAM10 and MMP9 may contribute to synaptic
plasticity by the proteolytic processing of essential synaptic adhesion
molecules, such as neuroligins and cadherins. Proteases expressed in glial
cells may modulate (in trans) the shedding events on postsynapses as well.
(C) The processing of amyloid precursor protein (APP) and the cellular prion
protein (PrPc) is an essential element in the molecular pathogenesis of
Alzheimer and Prion Disease, respectively. The reported identification of
physiological (Sfrp1) and pharmacological (acitretin) modulators of their
proteolytical processing adds new perspective to protease function.
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traﬃcking of ADAM10 from the endoplasmic reticulum to its
active site, the plasma-membrane, seems to be tightly controlled.
Some members of the tetraspanin (TSPAN) family, including
TSPAN15, associate with ADAM10 and are co-transported at the
cell surface (Prox et al., 2012), where they apparently increase
the life span of ADAM10 and help mediating substrate speciﬁcity
(Figure 1A).
Elena Marcello from Monica Di Luca´s (University of Milan,
Italy) laboratory also supported the idea that traﬃcking of
ADAM10 is central to its regulation. The Synapse-Associated
Protein-97 (SAP97) interacts with the cytoplasmic domain of
ADAM10 (Marcello et al., 2007). This binding leads to transport
of the protease to the post-synaptic membrane and in an
Alzheimer Disease (AD) context causes an increased α-secretase
cleavage of APP. The SAP97 contact to ADAM10 is further
regulated by protein kinase C phosphorylation (Saraceno et al.,
2014). Furthermore, the adaptor protein 2 (AP2) complex
controls ADAM10 endocytosis, which is triggered by long-
term-potentiation in hippocampal neurons, thereby reducing
its surface shedding function. Of note, this ADAM10/AP2
association seems increased in AD brains (Marcello et al.,
2013).
The synaptic role of ADAM10 was also the focus of
Taisuke Tomita´s (University of Tokyo, Japan) presentation.
The postsynaptic adhesion molecule neuroligin (NLG) binds to
its presynaptic counterpart neurexin. Interestingly, NLG muta-
tions have been linked to psychiatric disorders and mental
retardation (reviewed in: Sudhof, 2008). ADAM10 cleaves NLG-
1 after NMDA receptor activation. This causes an additional
intra-membrane cleavage exerted by the γ-secretase complex
(Suzuki et al., 2012). Dependent on neuronal stimulation, dif-
ferent members of the ADAM family may cleave diﬀerent types
of NLGs (Figure 1B). Therefore, ADAM proteases may be
interesting targets to treat autism spectrum disorders, because,
as mentioned above, NLGs have been strongly linked to these
neuropsychiatric diseases (Sudhof, 2008).
The challenge for considering ADAM proteases as therapeu-
tic targets will be the selective interference with the processing
of one substrate, without considerably aﬀecting other substrates,
so to avoid undesired side eﬀects. This is particularly important
because over 65 neuronal substrates have been so far identiﬁed, as
an example, for ADAM10. Some of these substrates were found
using proteomic techniques in the conditioned medium of neu-
rons derived from ADAM10 conditional knockout, as described
by Peer-Hendrik Kuhn (Technical University Munich, Germany).
This powerful approach not only validated a number of already
described substrates but extended this list to previously unrec-
ognized surface proteins involved in synapse function, axon
guidance and intercellular adhesion. A similar approach pre-
viously and successfully identiﬁed new neuronal substrates for
BACE-1, the β-secretase involved in APP processing (Kuhn et al.,
2012).
Again related to synaptic function, Leszek Kaczmarek (Nencki
Institute, Warsaw, Poland) described the pivotal importance of
matrix metalloproteinase-9 (MMP-9) in the regulation of synap-
tic plasticity (Figure 1B), learning, and memory. MMP-9 belongs
to the family of metzincins, which are enzymes secreted by
neurons and glia (Yong et al., 2001) and, in contrast to ADAMs,
their proteolytical activity occurs mainly in the extracellular space
(Figure 1B). MMP-9 expression is tightly regulated and it is
rapidly released near excitatory synapses in response to synap-
tic stimulation (Dziembowska et al., 2012). MMP9 cleaves the
cell adhesion molecule nectin-3 under conditions of stress (van
der Kooij et al., 2014) and its activity has been implicated in the
synaptic alterations found in neuropsychiatric disorders, such as
schizophrenia and autism (Tsilibary et al., 2014).
Metalloproteinases in Development
Nervous system development depends on exquisitely coordi-
nated cell communication, assuring that information among cells
is activated where needed and switched oﬀ at or prolonged for
the appropriate time. Controlled proteolysis contributes to this
coordination, among others, by disrupting adhesion, modulat-
ing signaling and even regulating gene transcription, thereby
inﬂuencing tissue patterning, morphogenesis and diﬀerentiation
(Bai and Pfaﬀ, 2011). Shanthini Sockanathan (Johns Hopkins
University, Baltimore, MD, USA) illustrated this idea presenting
a novel enzymatic mechanism, which controls Notch signaling,
a classical example of a pathway activated by the generation
of a transcriptionally active intracellular fragment (Pierfelice
et al., 2011). Indeed, the diﬀerentiation of postmitotic neurons
in the spinal cord depends upon the expression of GDE2, a six
trans-membrane protein with an extracellular glycerophospho-
diester phosphordiesterase (GDPD) domain (Sabharwal et al.,
2011). GDE2 expressed by motorneurons enzymatically con-
trol the surface availability of the Notch ligand Delta1 in motor
neurons, thereby promoting the diﬀerentiation of neighboring
progenitors by decreasing Notch activity. GDE2 control of sur-
face Delta occurs via a complex cascade that involves the GPI
anchor cleavage of the ADAM10 repressor RECK (Park et al.,
2013).
Avraham Yaron (Weizmann Institute of Science, Rehovot,
Israel) instead discussed the relevance of proteolytical inactiva-
tion of axon guidance signaling mediated by the Neuropilin-1
(Nrp1) receptor and its Sema3A ligand. Sema3A acts as an
axonal repellent for sensory axons projecting to the spinal cord.
Genetic inactivation of ADAM10/ADAM17 causes guidance
errors of proprioceptive axons, because the otherwise develop-
mentally regulated shedding of Nrp1 at the sensory growth cones
does not occur. This failed shedding abnormally prolongs the
growth cone repulsive response to Sema3A. Accordingly, this
repulsive response is no longer observed when growth cones
express a form of Nrp1 highly susceptible to cleavage, further
underscoring the importance of ectodomain shedding in switch-
ing growth cone responsiveness to guidance cues (Romi et al.,
2014).
Still within the concept of proper axon growth regulation but
this time of mouse retinal ganglion cells (RGC), Paola Bovolenta
(Centro de Biología Molecular Severo Ochoa, CSIC-UAM,
Madrid, Spain) presented data supporting that Secreted Frizzled
Related Proteins (Sfrps), highly diﬀusible secreted modulators of
cell–cell communication (Bovolenta et al., 2008), participate in
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mouse visual pathway development. Sfrps act by both directly
signaling at the growth cone and negatively modulating ADAM-
mediated proteolytical processing of other relevant cues (Marcos
et al., 2015). These conclusions are consistent with previous
observations demonstrating, on one side, that Sfrp1 reorients
chick and Xenopus RGC growth cones (Rodriguez et al., 2005)
and, on the other side, that Sfrp1 binds to ADAM10, down-
regulating the processing of a number of its substrates, including
N-cadherin or L1 (Esteve et al., 2011), which are involved in RGC
guidance.
Adhesion regulation is crucial also to establish the circuitry in
the developing cortex as discussed by Patricia Maness (University
of North Carolina at Chapel Hill, NC, USA). Alterations in the
function of GABAergic basket interneurons inhibiting pyrami-
dal cells of the prefrontal cortex are thought to be responsible
for working memory deﬁcits in schizophrenia patients. On the
other hand, ADAM-mediated proteolysis of NCAM is known
to participate in synaptic plasticity during learning and memory
(Brennaman et al., 2011). Taking the two observations together
Patricia showed that excessive shedding of NCAM is associ-
ated with a decreased GABAergic basket cell function and an
impaired working memory. This is because NCAM forms a
complex with EphA3, which binds to ephrinA5 and mediates
ADAM10-dependent elimination of basket cell synapses during
postnatal development of the prefrontal cortex. Disruption of this
complex increases basket cell perisomatic synapses and inhibitory
responses in the prefrontal cortex, indicating that this regulatory
mechanism may limit GABAergic inhibition in the cortex, estab-
lishing an appropriate excitatory/inhibitory balance (Brennaman
et al., 2013, 2014).
As other organs, the brain maintains stem cell niches through-
out adulthood. The mouse subependymal zone is one of these
niches, in which a relatively quiescent stem population contin-
ually produces new neurons through the generation of rapidly
diving, transit-amplifying progenitors (Porlan et al., 2013). Isabel
Fariñas (University of Valencia, Spain) showed that N-cadherin-
mediated adhesion to ependymocytes contributes to the quies-
cence of neural stem cells in the sub-ependymal niche. More
interestingly, MT5-MMP, a membrane-type metalloproteinase,
sheds N-cadherin ectodomain in this niche, ensuring the proper
activation of the stem cell population in both physiological and
regenerative conditions (Porlan et al., 2014), thus unveiling pos-
sible targets to stimulate neurogenesis when needed.
Following on the role of MMP, Lieve Moons (University
Leuven, Belgium) demonstrated that two members of this fam-
ily, MMP-2 and MMP-3, are required for the on-time migration
of granule cells and GABAergic interneurons in the cerebellum
as well as for a proper dendritic arborisation of the Purkinje cells
and pyramidal neurons of the neocortex (Santiago-Medina et al.,
2015). Notably, genetic inactivation of these MMP causes sus-
tained deﬁcits in motor performance in adult mice. Comparative
proteomic approaches highlighted possible underlying molecu-
lar causes (Van Hove et al., 2015). Furthermore, as an interesting
possibility linked to visual system repair, Lieve also discussed the
potential implications of MMP-2 and MT1-MMP as promising
axon-outgrowth promoting molecules within the CNS (De Groef
et al., 2014; Gaublomme et al., 2014).
Metalloproteinases in Neurodegeneration
γ-secretase-mediated intra-membrane proteolysis is a well-
deﬁned process, which involves regulated intra-membrane pro-
teolysis of type-1 trans-membrane proteins. Since APP is a major
substrate of the multi-protein γ-secretase complex and its cleav-
age contributes to the generation of amyloidogenic Aβ peptide
species, inhibition of the γ-secretase has attracted much atten-
tion as a promising therapy for AD. Bart de Strooper (University
Leuven, VIB, Belgium) discussed the possible causes of a failed
phase III clinical trial using semagacestat, a γ-secretase inhibitor.
Most likely owing to the inhibition of the Notch-1 signaling path-
way, patients treated with this small compound presented serious
side eﬀects, including skin cancers. Treated AD patients were
also subjected to infections and paradoxically experienced further
cognitive decline (Doody et al., 2013). A possible explanation for
this failure might be the potential need of lowering γ-secretase
enzymatic activity moderately but chronically, a kinetic that
might not have been achieved with the designed treating pro-
tocol. Rather, daily oscillations of the drug levels in the CSF
might have caused periods of full Notch inhibition, exacerbat-
ing the side eﬀects. Furthermore, the potential misprocessing of
other γ-secretase substrates might have also contributed to these
disappointing results (De Strooper, 2014). It is thus important
to design a more selective inhibition of the γ-secretase com-
plex capable of interfering with APP processing but not with
that of other substrates (De Strooper and Chavez Gutierrez,
2015).
Related to the crucial need in Alzheimer research of devel-
oping eﬀective therapies preventing the excessive generation of
Aβ species and following the idea that Sfrp1 is one of the
few soluble regulators of ADAM10, Pilar Esteve (Centro de
Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain)
showed that reduction of Sfrp1 expression shifts APP processing
toward a non-amyloidogenic pathway (Figure 1C) in the adult
mouse brain (Esteve et al., 2011). Nigel M. Hooper (University
of Manchester, UK) instead showed that ADAM10 sheds PrPC
(Taylor et al., 2009), the cellular prion protein (Figure 1C),
capable of binding, and mediating the toxicity of Aβ oligomers
(Rushworth et al., 2013). This leads to the hypothesis that mod-
ulation of the shedding of PrPC by ADAM10 would alter PrPC-
Aβ oligomers’ interaction and thus their neurotoxicity. Data in
this direction were presented, further supporting the idea that
increasing ADAM10 activity may be beneﬁcial for AD for mul-
tiple reasons. It will increase α-secretase processing of APP that
reduces Aβ and at the same time increases sAPPα generation,
thought to have neuroprotective properties, including the inhi-
bition of Aβ production (Obregon et al., 2012). Furthermore,
increased ADAM10-mediated shedding of PrPC will buﬀer the
toxicity of the remaining Aβ oligomers.
Kristina Endres (Clinic of Psychiatry and Psychotherapy,
Johannes Gutenberg University, Mainz, Germany) raised several
important considerations that need to be solved before pur-
suing ADAM10 as a therapeutic target. She underscored that
it is still unclear to what extent a deﬁcient ADAM10 catalytic
activity or a reduced expression of its gene participates in AD
pathogenesis. We also do not know the full network of factors
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regulating ADAM10 expression in humans and whether phar-
macological interference with ADAM10 enzymatic activity can
be achieved in patients. More importantly, is it safe? Kristina
reported encouraging results on both fronts with the identiﬁca-
tion of transcription factors that inﬂuence ADAM10 expression
(Reinhardt et al., 2014). She also showed that acitretin, a syn-
thetic retinoid, safely targets ADAM10 activity since AD patients
treated with this compound presented a signiﬁcant increase in the
CSF levels of sAPPα, providing important basis to design larger
and longitudinal trials to evaluate the possible clinical beneﬁts of
this treatment (Endres et al., 2014; Figure 1C).
The importance of metalloprotesases in neurodegeneration
is not limited to AD or autism spectrum disorders and the
case of another severely debilitating illness was illustrated.
Elena Cattaneo (University of Milan, Italy) reported the power
of combining evolutionary and developmental approaches to
study disease-genes such as that encoding the ancestral protein
Huntingtin. Expansion over 36 residues of a polymorphic tri-
nucleotide CAG repeat, translated into polyglutamine, causes
Hungtington Disease (HD), a genetically dominant and fatal neu-
rodegeneration (Zuccato and Cattaneo, 2014). Huntingtin exerts
a number of activities in the adult brain, such as promoting the
transcription of the neurotrophin BDNF (Zuccato et al., 2001),
critical for the survival and activity of the neurons that degener-
ate in HD. Unexpectedly, huntingtin has also evolved to acquire
the unique regulatory activity of controlling neural adhesion
by inhibiting ADAM10-mediated processing of N-cadherin (Lo
Sardo et al., 2012). Besides developmental implications, these
observations suggest that ADAM10 might be explored as a new
target in the treatment of HD (Lo Sardo et al., 2012).
Conclusion and Perspectives
Altogether the ﬁndings clearly highlighted that metalloproteases
are instrumental for proper development of the CNS and of
the embryo in general. Most of the basic developmental pro-
cesses in the CNS involve some type of metalloproteases, which
in general exert a beneﬁcial role: they activate pathways that
promote neurogenesis, regulate the migration of neurons or the
correct growth of axons to their ﬁnal destinations. Most of the
evidence so far indicates that metalloproteases regulate the lat-
ter process by degrading axon guidance cues, such as netrin
and its receptor DCC or Eph-ephrin molecules (Bai and Pfaﬀ,
2011). Nevertheless, the recent identiﬁcation of metalloprotease-
enriched “invadosomes” in the growth cones of all the neu-
rons so far tested (Santiago-Medina et al., 2015), suggests that
metalloproteases might tune other class of molecules such as
those involved in focal adhesion. Although not touched upon in
this workshop, metalloproteases also cooperate for proper axon
myelination and the formation of the extensive vasculature of
the brain (Yong et al., 2001). Other developmental events are
also likely to require proteases’ function. For example, brain col-
onization by microglial cell is a poorly explored phenomenon
that resemble metastatic invasion, a process in which metallo-
proteases have a well-established role (Mochizuki and Okada,
2007). Furthermore, microglia cell and astrocytes participate in
the regulation of synaptic plasticity and it is quite likely that part
of their roles might be mediated by secreted or membrane bound
proteases, acting in cis or even in trans, as mentioned.
Unfortunately, metalloproteases are not always associated to
positive events, as their activation or over-activation is often
detrimental. As discussed in the workshop, neurodegenerative
disorders are a primary example of harmful eﬀect together
with metastatic disorders. The role of metalloproteases in these
pathologies has been the focus of several laboratories for many
years. More recently, general pathological processes such as
neuroinﬂammation have emerged as metalloprotease-regulated
events, broadening the implication of these molecules. Thus, it
is apparent that we are just observing the tip of the iceberg as
we still know little of the physiological relevance of metallopro-
teases in the brain. Full understanding of their function might
unravel how the same protease can have a double edge and might
give us some hints on how to turn metalloproteases’ detrimental
side into a beneﬁcial activity. Reaching this degree of comprehen-
sion requires answering a large list of questions, and we would
like to point out some of them, which perhaps represent the most
obvious ones (Table 1).
Likely, more protease activities needs to be identiﬁed. The
number of substrates each protease can cleave seems to be large.
What is the spectrum of substrates used by a speciﬁc protease
under a given physiological condition? Is there substrate speci-
ﬁcity and how is it established? Do proteases compete for the
same substrate and how coordination among diﬀerent proteases
is achieved? How is their expression regulated? The physiolog-
ical modulators of protease activity are also largely unknown:
how many are there? Are they speciﬁc, likely contributing to
deﬁne protease/substrate interaction and how do they inﬂuence
developmental decisions and tissue homeostasis? What is the
contribution of ADAMs and MMPs to excitatory and inhibitory
synapse formation and homeostasis? How far can proteases act in
trans in the CNS?
Answering all these questions will certainly lead to a better
understanding of metalloproteinase biology but it will require
the development of new experimental tools and animal mod-
els. For example, there is the need of more sophisticated pro-
teomic approaches, which together with the generation of speciﬁc
antibodies will be instrumental to fully understand the spectrum
TABLE 1 | Main open questions in the field of neurobiology linked to
protease activities.
What is the portfolio of substrates of a given protease under different conditions?
How is substrate specificity established and modulated?
How does a protease network in a given cell work? How many proteases can use
the same substrate and in which sequence?
How can a protease activity be physiologically modulated? What are the protein or
lipid factors affecting protease function?
What are the factors affecting protease function in specific tissues or specific
developmental processes?
Which signaling processes control intra- and extracellular active proteases?
How do proteases protect themselves from proteolytic activity?
Are proteases suited as therapeutic targets to modulate their activity in the CNS?
Can proteolytical activity be exploited to favor CNS regeneration or neurological
diseases?
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of peptides generated by ectodomain shedding or by other types
of protease activities. The generation of knock-in mouse mutants
with deﬁnedmutations in diﬀerent protease domains should help
exploring their precise function and also model human diseases.
Furthermore, the recent introduction of new genome editing
techniques might be instrumental to tag metalloprotease or their
substrates, which could help following proteolytical events and
the ﬁnal destiny of the end products. Most of the work in metallo-
proteases has been performed in cell lines or mammalian models,
but other experimental species, such as the zebraﬁsh, might
become handy, especially to tackle metalloprotease implication
in developmental events in vivo.
When considering the devastating frequency of developmen-
tal (autism spectrum disorders) and neurodegenerative (AD and
Prion Disease) disorders so far known to be associated to the
impaired activity of metalloropeases, it is evident that improv-
ing our understanding of metalloprotease biology may have
important social beneﬁts, in addition to a scientiﬁc relevance.
As mentioned above, there is already a considerable eﬀort in
exploiting metalloproteases for therapeutics purposes. The task
is huge as a protease-targeted therapy will need careful eval-
uation and it is expected to work only in a tight therapeutic
window. Unwanted side eﬀects explained by the modulation of
other protease-substrate complexes have to be taken into consid-
eration. Nevertheless, there are considerable expectations that we
all hope to foster in the years to come.
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